We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Allogeneic BMT in patients above 45 years of age: a single center experience.
- Authors
Lysák, D; Koza, V; Jindra, P; Vozobulová, V; Schutzová, M; Fišer, J; Černá, K; Karas, M; Škopek, P; Švojgrová, M; Vokurka, S
- Abstract
Increasing age has been reported to be associated with worse outcome and higher occurrence of complication after allogeneic bone marrow transplantation. We analysed a cohort of 39 patients between the ages of 45 and 57 (median 49 years) with different hematologic malignancies who had undergone BMT in our institution over the preceeding 4 years. Pretransplant conditioning consisted of Bu/CY2, GVHD prophylaxis of a combination of cyclosporine and ‘short’ methotrexate. At present 54% of patients remain alive (with a median follow-up 44 months), the probability of survival at 5 years is 53% (5-year DFS 78%). The 5-year survival probability in the control group of younger patients is 53% (P = 0.8003). Main causes of death were GVHD (4 patients, 10%), relapse (5 patients, 13%) and infection (6 patients, 15%). The incidence of acute GVHD grade II–IV was 51% (grade III–IV 0% patients), the incidence of chronic GVHD 49% (limited 18% and extensive 31% patients). Our results suggest that allogeneic BMT can be performed in patients above the age of 45 years with acceptable morbidity and mortality, especially if a family HLA matched donor is available. Bone Marrow Transplantation (2001) 27, 723–726.
- Subjects
BONE marrow transplantation; GRAFT versus host disease
- Publication
Bone Marrow Transplantation, 2001, Vol 27, Issue 7, p723
- ISSN
0268-3369
- Publication type
Article